

The **next generation** biomaterial for soft-tissue augmentation

OEMUS MEDIA, Germany



On 17 January 2020, Camlog DACH organised the first NovoMatrix™ expert round table in Wimsheim, Germany. At this meeting, the clinicians involved in the pre-launch phase, gathered to exchange and discuss their experiences with the new biomaterial. After the presentation of the clinical and pre-clinical studies performed by Dr Gerhard Iglhaut (Germany) and Dr Edward Pat Allen (USA), the experts split in six groups to share and discuss their clinical experience. Each round table focussed on one of the following indications: gain of keratinised tissue, recession coverage, or augmentation of soft tissue around implants. The meeting was considered a great success by the participants. The content and structure of the meeting was regarded as highly scientific and was appreciated by the experts.

The following fundamental messages could be extracted from the expert round table: the exceptional handling characteristics and contoured shape are well suited for soft-tissue augmentations around teeth and implants, root recession coverage, and are designed to be used with different surgical techniques, to reduce time for product trimming, and to make intraoperative placement easier and more predictable. There was a consensus that additional clinical testing is needed, including long-term follow-up and further clinical studies with NovoMatrix™. However, very good healing could already be seen in early stages.

For over 20 years, LifeCell™, an Allergan affiliate and leading global medical technology company, has been developing in-

Fig. 1: The participants of the recently held NovoMatrix™ expert round table with the Camlog team.



© Camlog

Fig. 2: Dr Gerhard Iglhaut (Germany), a pioneer in the use of NovoMatrix™, at the expert round table.

novative products for the use in a wide range of applications. BioHorizons and Camlog have joined forces with LifeCell™ to bring NovoMatrix™, the next generation of soft-tissue augmentation material, into dentistry.

About NovoMatrix™

NovoMatrix™ is an acellular dermal matrix consisting of tissue-engineered porcine material. It is a breakthrough in xenogeneic processing ensuring a structurally intact, undamaged scaffold that supports cell and microvascular ingrowth. The proprietary tissue processing allows for rapid revascularisation, cell repopulation and minimal inflammation. The product comes in a pre-hydrated and ready-to-use state and offers a true alternative to autogenous soft-tissue grafts and current products on the market.

Indications and clinical evidence

When choosing a biomaterial, there is a strong demand in clinical practice for predictable outcomes. The NovoMatrix™ indications include guided tissue regeneration procedures in recession defects for root coverage, localised gingival augmentation to increase keratinised tissue around teeth and alveolar ridge reconstruction for prosthetic treatment. Dr Edward Pat Allen, one of the pioneer users of the novel biomaterial, says: “NovoMatrix™ graft exhibits uniform physical characteristics and great surgical handling, enhancing its ease of use in the tunnelling technique. This results in an excellent clinical outcome with minimal postoperative swelling and inflammation.”

After his workshop held at Osteology Barcelona last year, Dr Gerhard Iglhaut said about NovoMatrix™: “By using connective tissue grafts in the past, we had great outcomes and predictable results. But for the patients, the wound on the pallet was the most compromising challenge. We tried using new materials to avoid harvesting from the pallet, to have a second wound. And today

we have an acellular dermal matrix with porcine materials in Europe that overcomes this challenge. It is solid and it’s a little smoother, so in a minimally invasive tunnelling technique it helps us to slip it in and to suture it properly to residual tissue, which could be a challenge with connective tissue grafts.”

The national prelaunch is currently being implemented in EU countries taking into consideration the take-home messages learnt from the expert round table. As of yet, February 2020, over 100 key opinion leaders are already using NovoMatrix™ and they are exciting about the preliminary clinical results.

About BioHorizons and Camlog

BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologic products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education according to highest standards. For more information, visit www.biohorizonscamlog.com.

Editorial note: References can be obtained from Camlog and BioHorizons upon request.

contact

Branislav Kostadinov

Senior Product Manager Biomaterials Europe
BioHorizons Camlog
branislav.kostadinov@camlog.com